• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    6/29/26 5:10:12 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HELP alert in real time by email
    6-K 1 cybininc-form6xk06x29x2026.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of June, 2026.
    Commission File Number: 001-40673


    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F □ Form 40-F ⊠

    INCORPORATION BY REFERENCE
    Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-292294) of the Company, as amended or supplemented.




    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    CYBIN INC.
    (Registrant)
     
    Date:June 29, 2026By:
    /s/ Greg Cavers    
    Name:Greg Cavers
    Title:Chief Financial Officer





    EXHIBIT INDEX

    99.1
    News Release dated June 29, 2026

    Get the next $HELP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HELP

    DatePrice TargetRatingAnalyst
    4/13/2026$8.00Buy
    TD Cowen
    2/2/2026$22.00Buy
    Jefferies
    More analyst ratings

    $HELP
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    7/16/26 3:17:26 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Cybin Inc.

    D - CYBIN INC. (0001833141) (Filer)

    7/15/26 8:32:38 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Cybin Inc.

    D - CYBIN INC. (0001833141) (Filer)

    7/15/26 8:30:23 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

    Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataAPPROACH topline data readout on track for Q4 2026 1,2HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration ("FDA")HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using more

    7/21/26 10:54:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

    Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.

    7/21/26 9:00:00 AM ET
    $CMPS
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

    Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso

    7/21/26 8:30:00 AM ET
    $ATAI
    $CMPS
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Helus Pharma with a new price target

    TD Cowen initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $8.00

    4/13/26 8:52:11 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Helus Pharma with a new price target

    Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

    2/2/26 6:51:26 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Leadership Updates

    Live Leadership Updates

    View All

    Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

    Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, eviden

    4/16/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

    Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

    3/12/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

    In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

    2/24/26 7:45:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care